NCT02006667View on ClinicalTrials.gov

A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Urinary Tract Cancer
Interventions
DRUG

trastuzumab

4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression

DRUG

gemcitabine

1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6

DRUG

cisplatin

70 mg/m2 i.v. on Day 2 of Cycles 1 through 6

Trial Locations (7)

35043

Marburg

36043

Fulda

92637

Weiden

06449

Aschersleben

06846

Dessau

04103

Leipzig

04277

Leipzig

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02006667 - A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer | Biotech Hunter | Biotech Hunter